Abstract:One of the major causes of failure of vascular interventions is neointimal hyperplasia (NIH). To prevent the development of NIH, drugs must be delivered locally, for which drug-eluting, resorbable polymer scaffolds present a promising strategy (Liechty et.al., 2010). In this study, dipyridamole (DPA)-eluting scaffolds based on polyethylene glycol (PEG) and polycaprolactone (PCL) were fabricated and tested. PCL (MW 80,000) and PEG (MW 8000) were blended in chloroform at 3:1, 1:1, and 1:3 mass ratios for a final polymer concentration of 200 mg/mL. DPA was added at 0.1 mg/mL. Electrospinning was done with Avecta’s Spraybase system at 1 mL volume, 1 mL/hr flow rate, 15.0 kV voltage, and 15 cm distance. Bilayer scaffolds were fabricated with a layer containing DPA on a layer without DPA. Scaffolds were characterized by scanning electron microscopy (SEM) and porosity and tested for DPA release, cell proliferation, and blood biocompatibility. SEM images of the electrospun scaffolds revealed that adding PEG to PCL decreased the fiber diameter and pore size of the scaffolds. Scaffolds fabricated from 3:1 PCL:PEG demonstrated the slowest cumulative rate of release, with 9.17% cumulative release after 8 days. Scaffold fabricated from 3:1 PCL:PEG also exhibited higher levels of cell attachment and proliferation. With the 3:1 bilayer, RF24 endothelial cells proliferated on non-eluting side (luminal), while MOVAS smooth muscle cells were inhibited on DPA-eluting side (adventitial). No scaffolds showed significant hemolysis and clotting upon contact with blood. Significant differences were observed when compared to positive control (multiple t-tests, P < 0.001). PCL and PEG blended scaffolds in a 3:1 PCL:PEG mass ratio demonstrate slow and sustained drug release, adjustable cell proliferation properties, and biocompatibility, making for potential graft candidates. This approach may also be used for local and controlled release of other drugs, such as chemotherapeutic agents.

High Dose Progesterone Loaded PCL‐Polysorbate 80 Transdermal Fibers for Potential Application in Gynecological Oncology

Effect of drug encapsulation and sterilization process on physicochemical properties and release of combined steroid hormones from poly (ε-caprolactone) fibers

Electrospray doxorubicin‐loaded polycaprolactone‐polyethylene glycol nanospheres/poloxamer‐chitosan thermogel: A promising candidate for clinical applications

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

Modulating Drug Release from Short Poly(ethylene Glycol) Block Initiated Poly(L-lactide) Di-block Copolymers

Incorporating surfactants into PCL microneedles for sustained release of a hydrophilic model drug

Electrospun Ibuprofen-Loaded Blend PCL/PEO Fibers for Topical Drug Delivery Applications

Application of Fluorescent Composite Materials as a Sustained Release System in Treatment of Polycystic Ovary Syndrome

Tuning the Emulsion Properties Influences the Size of Poly(Caprolactone) Particles for Drug Delivery Applications

Fabrication of controlled-release polymeric microneedles containing progesterone-loaded self-microemulsions for transdermal delivery

Preparation and characterization of progesterone dispersions using supercritical carbon dioxide

Recent trends on polycaprolactone as sustainable polymer-based drug delivery system in the treatment of cancer: Biomedical applications and nanomedicine

Drug Packaging and Delivery Using Perfluorocarbon Nanoparticles for Targeted Inhibition of Vascular Smooth Muscle Cells

Estradiol-Loaded Poly(ε-caprolactone)/Silk Fibroin Electrospun Microfibers Decrease Osteoclast Activity and Retain Osteoblast Function

The engineering, drug release, and in vitro evaluations of the PLLA/HPC/ Calendula Officinalis electrospun nanofibers optimized by Response Surface Methodology

Development, characterization, and ex vivo evaluation of an insert for the ocular administration of progesterone

Functional copolymer coatings on electrospun fibers via photo‐initiated chemical vapor deposition

Abstract No. 433 Dipyridamole-loaded electrospun polymer scaffold based on polyethylene glycol/polycaprolactone for localized drug delivery

Polycaprolactone-Vitamin E TPGS Micellar Formulation for Oral Delivery of Paclitaxel

Development of Vaginal Carriers Based on Chitosan-Grafted-PNIPAAm for Progesterone Administration

Attachment of nanoparticulate drug-release systems on poly(ε-caprolactone) nanofibers via a graftpolymer as interlayer